Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New headset lets ALS patients type with their brain

NCT ID NCT04380649

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new, comfortable headset that reads brain signals to help people with ALS type on a virtual keyboard. The goal is to improve the device so it can be used in daily life. Five people with ALS will try the headset, and researchers will measure how easy it is to set up and use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

5 people

The number who actually took part.

Started

Feb 2023

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria 1. Age ≥ 18 years old 2. For women of childbearing potential, use of contraception for the duration of the study 3. Diagnosis of suspected ALS, possible, probable with ENMG, probable, defined according to the criteria of the World Federation of Neurology (revised El Escorial criteria, Airlie House Conference 1998) 4. Understanding of the objective of the study after describing the principle of the P300 Speller and the course of the study 5. Ability to follow the study procedure and to comply with the schedule of visits when entering the study 6. Expression of a P300 wave under the conditions of the study Exclusion criteria 1. Psychiatric illness or dementia that may interfere with the patient's ability to follow study procedures 2. History of photosensitive epilepsy 3. Patient subject to protective measures 4. Non-correctable visual disturbances 5. Limited ability to concentrate. 6. Women who are pregnant or breastfeeding or who have planned a pregnancy during the course of the study. 7. Persons deprived of their liberty by a judicial or administrative decision

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alternative communication devices are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis motor neuron disorder nervous system disorder neurodegenerative disease neuromuscular disease spinal cord disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alternative communication devices Amyotrophic lateral sclerosis Motor neuron disease Nervous system diseases Neurodegenerative diseases Neuromuscular diseases Spinal cord diseases

Contacts and locations

Locations

  • CHU de Nice

    Nice, Provence-Alpes-Côte d'Azur Region, 06000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.